CeV

Treatment tested

• Repetitive Transcranial Magnetic Stimulation

Other measures (2)

Inclusion Criteria: 1. Signed informed consent. 2. Age ≥ 18 years and less than 71 years. 3. Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018). 4. EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more. 5. Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening. 6. Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic treatment of spasticity (baclofen, tizanidine, botulinum toxin etc.) during the study. 7. No change in disease modifying therapy for at least 3 months prior to screening. 8. Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol. Exclusion Criteria: 1. Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study. 2. Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation. 3. Pregnant or breastfeeding or intending to become pregnant during the study. 4. Any previous rTMS therapy for any indication. 5. Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker. 6. Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study.

Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.